Clinical utility of signal-averaged ECG in ventricular arrhythmias

The clinical utility of signal-averaged electrocardiography lies in its ability to expose small, delayed ventricular activation signals that may be hidden in a standard 12-lead trace. By averaging many aligned beats, it reduces random noise and can identify late potentials associated with myocardial scar, conduction delay, and certain inherited arrhythmia syndromes.

For patients with premature ventricular contractions, nonsustained ventricular tachycardia, sustained VT, or ventricular fibrillation, this information can support a more focused assessment. Signal-averaged ECG is an adjunct rather than a stand-alone diagnostic test, so its findings must be interpreted alongside symptoms, rhythm monitoring, echocardiography, cardiac MRI, and electrophysiology assessment.

How signal-averaged ECG works

Signal averaging uses a high-resolution ECG system to align and average numerous consecutive, normally conducted QRS complexes. The averaged complexes are then filtered to suppress high-frequency noise and analysed in the time domain. A finding called a late potential may emerge when depolarisation through diseased myocardium occurs late and at low voltage.

Typical measurements include filtered QRS duration, terminal activation duration, and the root mean square voltage of the final 40 milliseconds. Prolongation of the filtered QRS together with low terminal voltage raises concern for delayed activation. Cut-offs depend on the recording system, filter frequency, selected leads, and the laboratory’s reference population.

The technology has historical roots in post-infarction risk assessment, when late potentials were associated with subsequent re-entrant ventricular tachycardia. Modern high-resolution averaging, spatial mapping, and cardiac MRI have broadened its research applications. Even so, a technically adequate signal-averaged report does not itself establish a diagnosis, prognosis, or treatment indication.

Role in assessing ventricular arrhythmias

The most useful clinical question is not whether signal averaging can label every abnormal rhythm, but whether late potentials would change the next diagnostic step. It adds little to the direct identification of ventricular ectopy, VT burden, or QRS morphology, which are better assessed with a 12-lead ECG and ambulatory rhythm monitor. Its contribution is to characterise myocardial electrical substrate.

In a patient with prior myocardial infarction, persistent late potentials may support the presence of an arrhythmogenic border zone around scar. This can provide mechanistic context for monomorphic VT and complement assessment of ventricular function and coronary disease. It is rarely sufficient, however, to decide whether an implantable cardioverter-defibrillator is indicated.

A positive result can also justify closer evaluation with cardiac MRI, exercise testing, or electrophysiology study when symptoms and routine tests leave meaningful uncertainty. A negative result does not exclude scar-related VT because some substrates fail to produce detectable late potentials. Signal averaging is most informative when the clinical suspicion is specific and the result fits the rest of the evaluation.

Structural disease and inherited channelopathies

In structural heart disease, late potentials may point to slow, fragmented conduction through fibrosis, particularly after infarction or in non-compaction and other cardiomyopathies. In suspected arrhythmogenic right ventricular cardiomyopathy, late potentials in right precordial leads can support the Task Force Criteria when complete right bundle-branch block is absent. They should still be weighed against T-wave inversion, epsilon waves, ventricular arrhythmia morphology, imaging, family history, and genetic evidence.

Signal-averaged ECG also has a role in selected inherited arrhythmia evaluations. Right-precordial late potentials have been reported in Brugada syndrome, although they are not specific enough to replace a diagnostic ECG, clinical history, sodium-channel testing when appropriate, or expert review. In long-QT and other channelopathies, QT interpretation, exercise-recovery patterns, medication exposure, and family history usually carry greater diagnostic weight.

The value therefore depends on phenotype. A family member with unexplained syncope, a young survivor of ventricular fibrillation, or a patient with a borderline standard ECG may benefit from an electrophysiology centre that uses signal averaging as one component of a broader work-up. Routine screening of low-risk relatives with a single ambiguous finding is less compelling.

Use in Australian clinical practice

Australian practice shapes how this investigation reaches patients. Australia’s Medicare scheme subsidises medically referred ECGs and ambulatory monitoring, while cardiology and electrophysiology care is divided between public hospitals and private services. Access to signal averaging varies, so a GP may need to arrange a referral to an electrophysiology clinic rather than request it locally. Patients should check Medicare and private-insurer arrangements before testing.

Distance matters outside metropolitan areas. Regional hospitals around Adelaide, Darwin, Cairns, and smaller inland centres may rely on couriered Holter devices and store-and-forward ECG review, with detailed interpretation provided by tertiary teams in Melbourne, Sydney, Brisbane, Perth, or Adelaide. Telehealth helps discussion, but it cannot compensate for poor signal quality or an inadequate recording.

In services caring for First Nations communities, cultural safety, Aboriginal health liaison roles, and professional interpreters can be integral to an appropriate pathway. Plain-language explanations are especially important because “SAECG” has little meaning outside specialist practice; Australian patients may understand an “ECG trace” or “heart monitor” more readily. Australian and New Zealand resuscitation guidance also informs counselling when arrhythmic risk and sudden death are discussed.

Technical limitations and interpretation

Recording quality is central to validity. Tremor, electrical interference, unstable electrode contact, frequent ectopy, atrial fibrillation, conduction block, and paced rhythms can distort the averaged signal or make interpretation unreliable. The technician must record enough clean, regular complexes and confirm that the patient remained still; an automated “normal” or “abnormal” label cannot replace review of the source trace.

Reference thresholds are not universal. Results can differ with 25-Hz versus 40-Hz filtering, lead selection, averaging method, and manufacturer, and older cut-offs may not transfer cleanly to contemporary equipment or diverse populations. Laboratories should state the technique and provide the measured filtered QRS duration and terminal voltage rather than relying on a binary result alone.

Clinical evidence is similarly bounded. Signal-averaged ECG has not become a routine screening test for ventricular arrhythmia because predictive performance depends on the population and outcome studied, while false positives are possible. It may add useful evidence in a selected referral, but it should not delay urgent evaluation of haemodynamic instability, sustained VT, or suspected cardiac arrest.

From signal findings to patient management

A practical pathway starts with the presenting event. Clinicians review the 12-lead ECG, symptom account, medication and family history, echocardiogram, and any stored rhythm or Holter report. If structural disease, scar, or an inherited syndrome remains plausible, cardiac MRI and referral to an electrophysiology specialist can clarify risk. Signal averaging is then used deliberately, with a pre-specified question about conduction delay or substrate.

Its findings may influence follow-up, medication review, exercise assessment, ambulatory monitoring, or electrophysiology study, but major interventions require stronger evidence. Catheter ablation decisions generally depend on electroanatomic mapping of the arrhythmia substrate. When bradycardia or dyssynchrony also requires pacing, implant technique is a separate question; the Journal of Arrhythmia’s account of bundle branch area pacing explains that approach and its early results.

For an implantable cardioverter-defibrillator, decisions should integrate sustained VT or VF, reversible causes, ejection fraction, scar burden, inherited disease, functional status, and patient preferences. Signal-averaged late potentials may support the overall assessment in a carefully selected case, yet they cannot replace those validated factors. Clear documentation prevents an isolated laboratory finding from being overinterpreted.

Signal-averaged ECG has a focused role: it can reveal electrically abnormal substrate that may explain ventricular arrhythmia and sharpen an electrophysiology referral. Clinicians should record the technique, relevant measurements, and the specific way the result changed management, while patients can ask their cardiologist how the finding fits the whole diagnosis and treatment plan. The test is most useful when linked to a clear clinical question.

Journal of Arrhythmia invites clinicians and researchers to contribute original research, balanced reviews, and clinically focused analyses that advance responsible use of ventricular arrhythmia testing. Contributors should review the journal’s author guidance and use its electronic submission routes to bring high-quality findings to an international open-access readership.